ARG1 and myeloproliferative disorder: Besides the finding about specific T-cell responses against these major MPN mutations, there was also one study proposing an activation of Arginase-1-specific T-cells could be a novel immunotherapeutic strategy to target immunosuppressive and malignant MPN-cells and to combine this strategy with further immunotherapeutic compounds [175].